昭衍新药 (603127.sh)

今开: 最高: 成交量:

昨收: 最低: 成交额:

+ 收藏

财务分析(报告期)(昭衍新药)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2024年一季报2023年年报2023年三季报2023年中报2023年一季报2022年年报2022年三季报2022年中报2022年一季报
主要指标:
 营业收入(元) 324,809,103.672,376,486,797.101,587,079,779.381,012,077,288.18369,386,010.952,267,970,979.111,276,392,981.45776,881,166.02270,975,486.87
 营业利润(元) -293,008,274.73507,096,321.21392,084,940.00116,839,105.61214,369,686.981,225,638,852.29717,775,641.91420,659,608.41139,825,485.08
 利润总额(元) -293,130,015.64506,950,437.23391,985,180.41116,935,671.75214,328,923.941,240,002,329.56732,204,331.44435,147,886.36139,756,935.47
 净利润(元) -273,363,603.07391,552,561.64326,197,002.6589,508,170.24187,710,078.621,073,200,095.01630,972,596.29370,384,259.65124,879,519.42
 归属于母公司股东的净利润(元) -272,222,474.99396,992,565.79327,598,359.0590,627,154.09187,759,654.851,074,257,178.93632,033,151.04371,119,594.26125,347,354.57
盈利能力:
 销售毛利率(%) 32.8442.6243.7744.3251.7047.9049.7048.9751.69
 销售净利率(%) -84.1616.4820.558.8450.8247.3249.4347.6846.09
 净资产收益率(%) -3.334.824.121.182.40----
 总资产报酬率ROA(%) -3.173.492.690.411.94----
 投入资本回报率ROIC(%) -3.334.813.981.102.2613.978.505.041.73
营运能力:
 存货周转率(次) 0.110.670.410.270.11----
 应收账款周转率(次) 1.8011.7211.386.832.75----
 总资产周转率(次) 0.030.230.160.100.04----
偿债能力:
 资产负债率(%) 17.8717.4119.4721.4820.7220.9723.9030.4418.81
 股东权益比率(%) 82.1282.5780.4778.4679.2178.9676.0369.4981.10
 已获利息倍数(倍) 11.46-2.36-2.31-0.58-7.64-7.02-4.43-4.08-3.01
 流动比率 4.644.854.293.043.273.212.742.184.09
 速动比率 3.403.462.921.861.881.981.631.483.33
发展能力:
 营业收入增长率(%) -12.074.7824.3430.2736.3249.5448.9745.3334.82
 营业利润增长率(%) -236.68-58.63-45.38-72.2253.3190.65154.94141.9429.70
 税后利润增长率(%) -244.98-63.04-48.17-75.5849.7992.71154.85141.4034.27
 净资产增长率(%) -4.331.177.458.3815.0214.6812.4411.9110.11
 总资产增长率(%) -7.72-3.251.52-4.0117.7621.4022.8935.3017.33

前瞻产业研究院